TriangleHEALTH PROFESSIONAL · SOURCE READING
Tazemetostat
Source: Childhood Ovarian Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 3, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Tazemetostat is an EZH2 inhibitor that demonstrates activity against preclinical models of small cell carcinoma of the ovary with SMARCA4 loss.[10]
Source links and citations
Evidence (tazemetostat):
Two patients with small cell carcinoma of the ovary and SMARCA4 loss were enrolled in a phase I trial of tazemetostat.[11]
Source links and citations
Two patients with small cell carcinoma of the ovary and SMARCA4 loss were enrolled in a phase I trial of tazemetostat.[11]
One patient achieved a partial response, and one patient achieved prolonged stable disease.
Two patients with small cell carcinoma of the ovary and SMARCA4 loss were enrolled in a phase I trial of tazemetostat.[11]
The most common toxicities associated with tazemetostat were asthenia, anemia, anorexia, muscle spasms, nausea, and vomiting.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice